| ADC Therapeutics SA: ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update | LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026
Recent amendment to HealthCare... ► Artikel lesen |
| ADC Therapeutics SA: ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates | Preliminary unaudited fourth quarter and full year 2025 net product revenue of approximately $22M and $73M respectively; cash and cash equivalents of approximately... ► Artikel lesen |
| ADC Therapeutics SA: ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large ... | ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated an 89.8% ORR and 77.6% CR across the 49 efficacy-evaluable patients with a minimum of 6 months of... ► Artikel lesen |
| Dividendenbekanntmachungen (10.03.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADAIRS LIMITED AU000000ADH2 0,055 AUD 0,0334 EUR ALCOA CORPORATION US0138721065 0,1 USD 0,0859 EUR AMEREN CORPORATION US0236081024 0... ► Artikel lesen |
| ICL Posts Loss In Q4 | WASHINGTON (dpa-AFX) - ICL (ICL) reported fourth quarter net loss attributable to shareholders of $73 nmillion compared to profit of $70 million, a year ago. Loss per share was $0.06, compared... ► Artikel lesen |
| ICL To Acquire Bartek Ingredients In Two Phase Deal | WASHINGTON (dpa-AFX) - ICL Group Ltd (ICL), a chemical and specialty mineral company, on Thursday announced that it has entered into a definitive agreement to acquire Bartek Ingredients Inc.... ► Artikel lesen |